In Brief: Sensor Pad
This article was originally published in The Tan Sheet
Executive Summary
Sensor Pad: Sales restriction merits reconsideration by FDA, the House Appropriations Committee states in its FY 1997 budget. During budget mark-up this month, the committee unanimously accepted Rep. Barbara Vucanovich (R-Nev.)'s amendment directing FDA "to re-examine the need for `prescription-only' status" for the Inventive Products breast self-examination device and report its findings to Congress within 60 days of enactment. The amendment argues that the restriction "limits availability of this essential tool to low-income women who cannot afford to see a physician in non-emergency situations." Vucanovich introduced a bill (HR 3504) on May 22 that would require FDA to permit OTC distribution of the product...